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Conclusion  
SBRT to pulmonary metastases of oligo-metastatic NSCLC 
patients resulted in favorable LC and promising OS. This 
is the first study showing that histological NSCLC subtype 
is also an important predictor for LC in SBRT for 
pulmonary metastases and not only for primary NSCLC 
tumors. Further prospective studies are needed for 
evaluating whether treatment paradigms and irradiation 
doses might have to be adapted depending on different 
histological subtypes. 
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Purpose or Objective  
The majority of patients will develop systemic failure 
after radical local treatment using stereotactic body 
radiotherapy (SBRT) for oligo-metastatic disease. 
However, an oligo-recurrent pattern of disease 
progression is observed in a relevant proportion of 
patients, which offers the possibility of repeat radical 
local treatment. Experiences in repeat SBRT are very 
limited, which is in particular relevant in oligo-recurrent 
disease within the same organ due to a potentially 
increased risk for radiation-induced toxicity. Therefore, 
it was the aim of this study to evaluate safety and 
efficacy of repeat SBRT for pulmonary metastases. 
Material and Methods  
This study was performed on the DEGRO AG Stereotaxy 
database of 967 SBRT treatments for pulmonary 
metastases. Patients lost to follow-up within six months 
after SBRT were removed from the analysis, thus, 559 
patients with 753 SBRT treatments were evaluated. One 
SBRT treatment was defined as all SBRT fractions 
delivered to one pulmonary target, and all SBRT 
treatments performed within a one-month interval were 
defined as one SBRT course. Cox regression model, 
logistic regression and LASSO (Least Absolute Shrinkage 
and Selection Operator) method were used to analyze the 
association between the number of SBRT treatments, 
number and timing of multiple SBRT courses per patient, 
overall survival and the risk of early death within 3 and 6 
months after SBRT. Follow-up was measured from the 
start of the last SBRT treatment. 
Results  
Overall, 127 / 559 patients were treated with SBRT for 
multiple pulmonary oligo-metastases: 87 patients, 26 
patients, 8 patients and 6 patients were treated for 2 
metastases, 3 metastases, 4 metastases and >4 
metastases, respectively. All metastases were treated 
within one single SBRT course in 75 patients and repeat 
SBRT in ≥ 2 courses was performed in 58 patients, 
maximum 4 SBRT courses. The median interval between 
the first and second SBRT course was 5.9 – 8.7 months 
(range 1.8 - 69.0 months). Repeat SBRT was practiced for 
newly developed oligo-metastases and not as re-
irradiation after local failure. No grade 4 or grade 5 
toxicity was observed in the cohort of SBRT for multiple 
lesions and repeat SBRT. After a median follow-up of 15.7 
months, median OS was 23.3 months for the entire cohort 
and OS was not significantly influenced by the overall 
number of treated metastases or the timing of repeat 
SBRT. In total, 34 patients (6.1%) and 78 (14.0 %) patients 
died within 3 months and 6 months after their last SBRT 
course, respectively: the risk of early death within 3 and 
6 months was independent from the number of 
metastases and the number of SBRT courses. 
Conclusion  
The overall number of lung metastases and the timing of 
repeat SBRT did not significantly influence pulmonary 
toxicity, early death and overall survival. Repeat SBRT 
for pulmonary metastases should therefore be considered 
in carefully selected patients with oligo-metastatic 
disease. 
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Abstract text  
This talk will cover the rationale for using breath-holding 
techniques in radiotherapy for breast cancer, before 
discussing the available breath-hold techniques and how 
to implement them, with particular focus on the cost-
effective voluntary breath-hold technique. Finally, the 
talk will discuss the benefits and practicalities 
of combining breath-hold with more advanced 
radiotherapy techniques in order to treat the internal 
mammary chain. 
